By definition, a rare disease is one that only affects a handful of people in the world. But with more than 300 million people collectively affected by these conditions and only few approved treatments available, rare diseases constitute a major unmet medical need. Christina Ström Möller from Swedish biopharmaceutical company Sobi walks us through the scientific, commercial and human challenges of the rare disease landscape.
Tune in to find out:
Want to know more?
Read the stories of patients living with rare diseases on the Sobi website.
Show your support for Rare Disease Day on 28 February by sharing campaign materials online with the hashtag #RareDiseaseDay or joining one of the many events planned around the world.
Rare Disease Day is organised by EURORDIS-Rare Diseases Europe, a non-profit alliance of rare disease patient organisations from 73 countries.
When assessing the safety of rare disease medicines, also known as orphan drugs, it is important to include all available sources of data.
A recent review of orphan drug policies found that several low- and middle-income countries had developed such policies in the last decade – although disparities between countries with different income levels still remain.
A survey conducted by EURORDIS in 2020 found that the COVID-19 pandemic exacerbated the many challenges that people living with a rare disease face.
Join the conversation on social media
Follow us on Twitter, Facebook or LinkedIn, and share your thoughts about the show with the hashtag #DrugSafetyMatters.
Got a story to share?
We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!
About UMC
Read more about Uppsala Monitoring Centre and how we work to make medicines safer for patients.